Thiotepa

Generic Name: Thiotepa

Brand Names: Tepadina, Thiotepa Riemser

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₃PS

CAS Number: 52-24-4

Unique Ingredient Identifier: 905Z5W3GKH

Background: N,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years. It is a stable derivative of N,N',N''- triethylenephosphoramide (TEPA). It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. It is also used as conditioning for Bone marrow transplantation. Its main toxicity is myelosuppression.

Indication: ThioTEPA is used a as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients. Also, when high dose chemotherapy with HPCT support it is appropriate for the treatment of solid tumours in adult and paediatric patients.

Associated Conditions: Adenocarcinoma of the Ovaries, Breast Adenocarcinoma, Papillary transitional cell carcinoma of bladder, Malignant effusion

Associated Therapies: -

Clinical Trials

Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma

Phase 2

Withdrawn

Conditions: Lymphoproliferative Disorder
Small Intestine Cancer
Brain and Central Nervous System Tumors
Lymphoma

Interventions: Biological: autologous immunoglobulin idiotype-KLH conjugate vaccine
Biological: sargramostim
Drug: methotrexate
Drug: thiotepa
Radiation: radiation therapy

First Posted Date: 2008-02-22

Last Posted Date: 2018-11-26

Lead Sponsor: University of Texas Southwestern Medical Center

Registration Number: NCT00621036

Locations: 🇺🇸
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States

Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies

Phase 2

Terminated

Conditions: Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Myelodysplasia
Chronic Myeloid Leukemia

Interventions: Radiation: Total Body Irradiation
Drug: Thiotepa
Drug: Fludarabine
Biological: Rabbit ATG
Drug: Palifermin

First Posted Date: 2008-01-15

Last Posted Date: 2018-04-10

Lead Sponsor: Sherif S. Farag

Target Recruit Count: 9

Registration Number: NCT00593554

Locations: 🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States

Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma

Phase 3

Completed

Conditions: Localized Resectable Neuroblastoma
Localized Unresectable Neuroblastoma
Recurrent Neuroblastoma
Regional Neuroblastoma
Stage 4 Neuroblastoma
Stage 4S Neuroblastoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carboplatin
Drug: Cisplatin
Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Radiation: External Beam Radiation Therapy
Biological: Filgrastim
Drug: Isotretinoin
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Procedure: Peripheral Blood Stem Cell Transplantation
Other: Pharmacological Study
Drug: Topotecan Hydrochloride
Drug: Thiotepa
Drug: Vincristine Sulfate Liposome

First Posted Date: 2007-12-05

Last Posted Date: 2022-04-28

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 665

Registration Number: NCT00567567

Locations: 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Valley Children's Hospital, Madera, California, United States
🇺🇸
Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States

and more 187 locations

Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma

Phase 3

Active, not recruiting

Conditions: Extraocular Retinoblastoma

Interventions: Procedure: Autologous Bone Marrow Transplantation
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carboplatin
Drug: Cisplatin
Drug: Cyclophosphamide
Drug: Etoposide
Biological: Filgrastim
Procedure: In Vitro-Treated Peripheral Blood Stem Cell Transplantation
Radiation: Radiation Therapy
Drug: Thiotepa
Drug: Vincristine Sulfate

First Posted Date: 2007-11-07

Last Posted Date: 2024-10-22

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 60

Registration Number: NCT00554788

Locations: 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States

and more 70 locations

High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors

Not Applicable

Completed

Conditions: Adult Acute Lymphoblastic Leukemia in Remission
Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Adult Nasal Type Extranodal NK/T-cell Lymphoma
Childhood Acute Lymphoblastic Leukemia in Remission

Interventions: Drug: cyclophosphamide
Drug: etoposide
Drug: melphalan
Drug: busulfan
Radiation: total-body irradiation
Drug: carboplatin
Procedure: autologous-autologous tandem hematopoietic stem cell transplantation
Drug: carmustine
Drug: thiotepa
Procedure: autologous hematopoietic stem cell transplantation

First Posted Date: 2007-09-28

Last Posted Date: 2021-04-22

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 174

Registration Number: NCT00536601

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Leukemia

Phase 1

Completed

Conditions: Leukemia

Interventions: Biological: filgrastim
Drug: clofarabine
Drug: dexamethasone
Drug: thiotepa
Drug: topotecan hydrochloride
Drug: vinorelbine tartrate

First Posted Date: 2007-04-19

Last Posted Date: 2013-11-14

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 23

Registration Number: NCT00462787

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases

Phase 2

Terminated

Conditions: Leukemia
Graft Versus Host Disease
Myelodysplastic Syndromes

First Posted Date: 2007-03-22

Last Posted Date: 2017-05-24

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 1

Registration Number: NCT00450983

Locations: 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors

Phase 2

Completed

Conditions: Childhood Germ Cell Tumor
Ovarian Cancer
Teratoma

Interventions: Drug: carboplatin
Drug: etoposide
Drug: ifosfamide
Drug: paclitaxel
Drug: thiotepa
Procedure: autologous hematopoietic stem cell transplantation
Drug: Mesna
Biological: filgrastim

First Posted Date: 2007-02-07

Last Posted Date: 2022-05-17

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 23

Registration Number: NCT00432094

Locations: 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer
Metastatic Breast Carcinoma
Invasive Breast Carcinoma

Interventions: Drug: Carboplatin
Drug: Cyclophosphamide
Drug: Thiotepa
Procedure: Stem Cell Transplant

First Posted Date: 2007-01-31

Last Posted Date: 2013-04-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 32

Registration Number: NCT00429182

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease

Phase 1

Completed

Conditions: Graft Versus Host Disease
Leukemia
Myelodysplastic Syndromes

Interventions: Biological: filgrastim
Drug: clofarabine
Drug: melphalan
Drug: mycophenolate mofetil
Drug: tacrolimus
Drug: thiotepa
Procedure: allogeneic bone marrow transplantation
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2007-01-18

Last Posted Date: 2022-12-27

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 38

Registration Number: NCT00423514

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy